Cargando…

Vortioxetine as adjunctive therapy in the treatment of schizophrenia

BACKGROUND: The evidence for safe and effective interventions to treat the negative and cognitive symptoms of schizophrenia is lacking. OBJECTIVES: Vortioxetine is a novel antidepressant that has been used as adjunctive therapy for the treatment of psychosis; however, its effectiveness in clinical p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Redaelli, Sofia, Porffy, Lilla, Oloyede, Ebenezer, Dzahini, Olubanke, Lewis, Gabriella, Lobo, Maria, Whiskey, Eromona, Shergill, Sukhi S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272178/ https://www.ncbi.nlm.nih.gov/pubmed/35833056 http://dx.doi.org/10.1177/20451253221110014

Ejemplares similares

Clozapine haematological monitoring for neutropenia: a global perspective
por: Oloyede, Ebenezer, et al.
Publicado: (2022)

When the drugs don’t work: treatment-resistant schizophrenia, serotonin and serendipity
por: Lowe, Penelope, et al.
Publicado: (2017)

A retrospective case notes review of the effectiveness and tolerability of metoclopramide in the treatment of clozapine-induced hypersalivation (CIH)
por: Livermore, Cecilia, et al.
Publicado: (2022)

Real-world effectiveness of admissions to a tertiary treatment-resistant psychosis service: 2-year mirror-image study
por: Casetta, Cecilia, et al.
Publicado: (2020)

Benign ethnic neutropenia: an analysis of prevalence, timing and identification accuracy in two large inner-city NHS hospitals
por: Oloyede, Ebenezer, et al.
Publicado: (2021)

Closure beyond clozapine: successfully averting rebound symptoms in a patient with schizoaffective disorder and agranulocytosis
por: Green, Alastair, et al.
Publicado: (2019)

Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
por: Taylor, David, et al.
Publicado: (2022)

Management of clozapine treatment during the COVID-19 pandemic
por: Gee, Siobhan, et al.
Publicado: (2020)

M106. VIRTUAL-REALITY COGNITIVE TRAINING AND ASSESSMENT IN SCHIZOPHRENIA
por: Porffy, Lilla, et al.
Publicado: (2020)

F77. OXYTOCIN ENHANCES VISUAL ATTENTION TO FACIAL STIMULI IN PATIENTS WITH SCHIZOPHRENIA: EVIDENCE FROM AN EYE-TRACKING STUDY
por: Porffy, Lilla, et al.
Publicado: (2018)

Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review
por: Oloyede, Ebenezer, et al.
Publicado: (2022)

Successful clozapine rechallenge following recurrent clozapine-associated pancreatitis: a case report
por: Rodriguez, Victoria, et al.
Publicado: (2020)

Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations
por: Krivoy, Amir, et al.
Publicado: (2021)

The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Alpha3/alpha2 power ratios relate to performance on a virtual reality shopping task in ageing adults
por: Patchitt, Joel, et al.
Publicado: (2022)

O6.8. GLUTAMATERGIC DYSFUCTION AND TREATMENT RESPONSE IN MINIMALLY TREATED AND CHRONIC SCHIZOPHRENIA PATIENTS
por: Mouchlianitis, Elias, et al.
Publicado: (2018)

A Novel Virtual Reality Assessment of Functional Cognition: Validation Study
por: Porffy, Lilla Alexandra, et al.
Publicado: (2022)

Virtual reality cognitive & functional assessment in psychosis
por: Shergill, Sukhwinder, et al.
Publicado: (2021)

T125. INCIDENCE OF TREATMENT RESISTANCE SCHIZOPHRENIA IN A COMMUNITY SAMPLE USING THE TRRIP CONCENSUS
por: Joyce, Dan, et al.
Publicado: (2018)

S148. DIFFERENTIAL NEURAL REWARD MECHANISMS IN TREATMENT RESPONSIVE AND TREATMENT RESISTANT SCHIZOPHRENIA
por: Vanes, Lucy, et al.
Publicado: (2018)

Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a case report
por: Patel, Sachin S, et al.
Publicado: (2010)

Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: A review of the literature
por: Patel, Sachin S, et al.
Publicado: (2010)

Clozapine discontinuation withdrawal symptoms in schizophrenia
por: Blackman, Graham, et al.
Publicado: (2021)

White matter changes in treatment refractory schizophrenia: Does cognitive control and myelination matter?
por: Vanes, Lucy D., et al.
Publicado: (2018)

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study
por: De Berardis, Domenico, et al.
Publicado: (2020)

Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report
por: Sanchez, Asiel Yair Adan, et al.
Publicado: (2016)

Change in plasma concentration of clozapine and norclozapine following a switch of oral formulation
por: Keshavarzi, Farinaz, et al.
Publicado: (2020)

Automatic Detection of Cognitive Impairment with Virtual Reality
por: Mannan, Farzana A., et al.
Publicado: (2023)

Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report — ADDENDUM
por: Sanchez, Asiel Yair Adan, et al.
Publicado: (2019)

A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia
por: di Hou, Meng, et al.
Publicado: (2021)

Resolution without discontinuation: heart failure during clozapine treatment
por: Whiskey, Eromona, et al.
Publicado: (2020)

Rehabilitation or Stagnation? a Six Month Mirror-Image Study Reviewing the Effectiveness of an Inpatient Rehabilitation Unit
por: Kapila, Adisha, et al.
Publicado: (2022)

T164. NETWORK CONNECTIVITY SUPPORTING REWARD LEARNING DIFFERENTIALLY DISRUPTED IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Horne, Charlotte, et al.
Publicado: (2020)

Possible pharmacogenetic factors in clozapine treatment failure: a case report
por: Whiskey, Eromona, et al.
Publicado: (2021)

F155. THE NEUROPHYSIOLOGICAL AND BEHAVIOURAL EFFECTS OF TRANSCRANIAL DIRECT CURRENT STIMULATION ON WORKING MEMORY AND EXECUTIVE FUNCTIONING IN SCHIZOPHRENIA
por: Orlov, Natasza, et al.
Publicado: (2018)

Which Cognitive Domains are Improved by Treatment with Vortioxetine?
por: Harrison, John E, et al.
Publicado: (2016)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Targeting Treatment-Resistant Auditory Verbal Hallucinations in Schizophrenia with fMRI-Based Neurofeedback – Exploring Different Cases of Schizophrenia
por: Dyck, Miriam S., et al.
Publicado: (2016)

Neuroimaging oxytocin modulation of social reward learning in schizophrenia
por: Mouchlianitis, Elias D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ek57aamr10h5frb564s1c9gpmf